Results 121 to 130 of about 740,964 (300)

IgG specific to SARS-CoV-2 RBD in (1) non-diagnosed for COVID-19 but positive for anti-SARS-CoV-2 IgG, (2) in patients hospitalized due to COVID-19, (3) and in vaccinated against SARS-CoV-2.

open access: yes, 2022
IgG specific to SARS-CoV-2 RBD in (1) non-diagnosed for COVID-19 but positive for anti-SARS-CoV-2 IgG, (2) in patients hospitalized due to COVID-19, (3) and in vaccinated against SARS-CoV-2.
Amelia Kardaś (12041991)   +15 more
core   +1 more source

A Generative Neuro‐Symbolic AI for Protein Sequence Design

open access: yesAdvanced Science, EarlyView.
We introduce EffieDes, a neuro‐symbolic framework coupling deep learning‐based fitness landscape parameterization with exact automated reasoning. Unlike greedy sampling, EffieDes identifies sequences that globally optimize fitness while satisfying intricate design constraints.
Marianne Defresne   +12 more
wiley   +1 more source

Polymorphism of SARS-CoV Genomes

open access: yesActa Genetica Sinica, 2006
In this work, severe acute respiratory syndrome associated coronavirus (SARS-CoV) genome BJ202 (AY864806) was completely sequenced. The genome was directly accessed from the stool sample of a patient in Beijing. Comparative genomics methods were used to analyze the sequence variations of 116 SARS-CoV genomes (including BJ202) available in the NCBI ...
SHANG, Lei   +6 more
openaire   +2 more sources

Sustained Delivery of a Shingles Subunit Vaccine Overcomes Age‐Related Declines in Humoral and Cellular Immunity Relative to Shingrix

open access: yesAdvanced Science, EarlyView.
Sustained delivery of a shingles subunit vaccine from an injectable polymer–nanoparticle hydrogel enhanced the potency, durability, and breadth of immune responses in aged mice while minimizing inflammatory cytokine production and reactogenicity. This strategy decouples immunogenicity from reactogenicity and offers a promising approach to improve ...
Ye Eun Song   +5 more
wiley   +1 more source

SARS-CoV-2 IgG and associated factors.

open access: yes, 2023
Non-pharmaceutical interventions remain key in mitigating the spread of SARS-CoV-2. We sought to assess COVID-19 preventive, social-behavioural practices, and SARS-CoV-2 exposure through IgG rapid tests.
Vittorio Colizzi (208609)   +20 more
core   +1 more source

Somatic Evolution of a Germline Antibody Expands its Breadth to Neutralize Early SARS‐CoV‐2 Omicron Variants

open access: yesAdvanced Science, EarlyView.
Engineering of the 148‐germline (148‐GL) antibody reveals a roadmap for overcoming SARS‐CoV‐2 viral escape. By introducing four specific somatic hypermutations, the resulting 148‐M4 variant restores potent neutralization against Omicron BA.1 and BA.4/5.
Huibin Lv   +14 more
wiley   +1 more source

SARS-CoV-2 case fatality presented for VA enrollees who tested positive for SARS-CoV-2 each monthly period from February 2020 to February 2021.

open access: yes, 2021
SARS-CoV-2 case fatality presented for VA enrollees who tested positive for SARS-CoV-2 each monthly period from February 2020 to February 2021.
Jacqueline M. Ferguson (11592220)   +13 more
core   +1 more source

SARS-CoV-2 reinfection

open access: yesMedicina Intensiva (English Edition), 2021
Romera, I.   +5 more
openaire   +3 more sources

Optimized Lipid Nanoparticles with Tail‐Modified Ionizable Lipids for Safer mRNA Delivery

open access: yesAdvanced Science, EarlyView.
Systematic engineering of hydrophobic tail architecture in vitamin B5‐derived ionizable lipids establishes a comprehensive structure–activity relationship framework for mRNA delivery. Combined lipidtail and formulation optimization identifies TM1‐OPT3‐C, a lipid nanoparticle platform that improves efficacy–safety balance through efficient mRNA delivery,
Seo‐Hyeon Bae   +27 more
wiley   +1 more source

Neutralization titers of SARS-CoV-2-nLuc and SARS-CoV-2 variants of concern with sera of macaques prime-boost vaccinated with rVSV-msp-SARS-CoV-2-Gtc.

open access: yes, 2021
Three macaques were prime-immunized intramuscularly with 109 PFU rVSVInd-SARS-CoV-2-msp-SF-Gtc and boost-immunized with 109 PFU of rVSVInd-SARS-CoV-2-msp-SF-Gtc 20 days after the prime-immunization.
Taewoo Kim (1456888)   +30 more
core   +1 more source

Home - About - Disclaimer - Privacy